NEW DELHI: India is likely to have a Covid-19 vaccine in the new year, India’s general drug controller VG Somani hinted on Thursday.
Speaking at a webinar, Somani said most importantly, industry and research organizations have stood the test of time.
He said that the vaccine candidates got the funding and also spoke about the efforts made by the Department of Biotechnology. “… and we’ll probably have a very happy new year with something in hand. That’s what I can hint at,” Somnai said.
The Serum Institute of India, Bharat Biotech and Pfizer have applied to DCGI for an emergency use authorization for their Covid-19 vaccine candidates and are awaiting approval.
Somani said the approval process was sped up in light of the pandemic by quickly processing all applications, allowing for parallel phase 1 and 2 testing without waiting for full data.
“There has been no compromise on the safety or efficacy of the data. The only thing is that the regulator has accepted partial data,” he said.
A panel of experts from the Central Drug Control Organization (CDSCO) that met Wednesday to consider IBS emergency use authorization requests for Oxford COVID-19 vaccine and Bharat Biotech’s ‘Covaxin’ will meet again on January 1 to continue deliberating on the matter.
The Matter Expert Committee (SEC) on Covid-19 on Wednesday deliberated and analyzed additional data and information submitted by the Serum Institute of India (SII) and Bharat Biotech.
Speaking at a webinar, Somani said most importantly, industry and research organizations have stood the test of time.
He said that the vaccine candidates got the funding and also spoke about the efforts made by the Department of Biotechnology. “… and we’ll probably have a very happy new year with something in hand. That’s what I can hint at,” Somnai said.
The Serum Institute of India, Bharat Biotech and Pfizer have applied to DCGI for an emergency use authorization for their Covid-19 vaccine candidates and are awaiting approval.
Somani said the approval process was sped up in light of the pandemic by quickly processing all applications, allowing for parallel phase 1 and 2 testing without waiting for full data.
“There has been no compromise on the safety or efficacy of the data. The only thing is that the regulator has accepted partial data,” he said.
A panel of experts from the Central Drug Control Organization (CDSCO) that met Wednesday to consider IBS emergency use authorization requests for Oxford COVID-19 vaccine and Bharat Biotech’s ‘Covaxin’ will meet again on January 1 to continue deliberating on the matter.
The Matter Expert Committee (SEC) on Covid-19 on Wednesday deliberated and analyzed additional data and information submitted by the Serum Institute of India (SII) and Bharat Biotech.
.
